Free Trial

China SXT Pharmaceuticals (SXTC) Competitors

China SXT Pharmaceuticals logo
$1.59 -0.03 (-1.85%)
Closing price 04:00 PM Eastern
Extended Trading
$1.59 0.00 (0.00%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SXTC vs. VIR, KALV, AMLX, AVBP, IMTX, IMNM, NUVB, MGTX, GYRE, and AUTL

Should you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include Vir Biotechnology (VIR), KalVista Pharmaceuticals (KALV), Amylyx Pharmaceuticals (AMLX), ArriVent BioPharma (AVBP), Immatics (IMTX), Immunome (IMNM), Nuvation Bio (NUVB), MeiraGTx (MGTX), Gyre Therapeutics (GYRE), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry.

China SXT Pharmaceuticals vs. Its Competitors

Vir Biotechnology (NASDAQ:VIR) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

China SXT Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -2,769.04%. China SXT Pharmaceuticals' return on equity of 0.00% beat Vir Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Vir Biotechnology-2,769.04% -47.46% -39.33%
China SXT Pharmaceuticals N/A N/A N/A

In the previous week, Vir Biotechnology had 4 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 5 mentions for Vir Biotechnology and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.87 beat Vir Biotechnology's score of 0.81 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Vir Biotechnology Positive
China SXT Pharmaceuticals Very Positive

China SXT Pharmaceuticals has lower revenue, but higher earnings than Vir Biotechnology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$74.21M10.52-$521.96M-$4.22-1.34
China SXT Pharmaceuticals$1.93M95.59-$3.10MN/AN/A

Vir Biotechnology presently has a consensus price target of $30.25, suggesting a potential upside of 435.40%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, research analysts plainly believe Vir Biotechnology is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vir Biotechnology
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88
China SXT Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Vir Biotechnology has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 16.0% of Vir Biotechnology shares are owned by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Vir Biotechnology beats China SXT Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get China SXT Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SXTC vs. The Competition

MetricChina SXT PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$187.96M$2.50B$5.70B$9.51B
Dividend YieldN/A1.75%4.69%4.01%
P/E RatioN/A9.0528.0720.05
Price / Sales95.59757.64448.5799.42
Price / CashN/A165.2136.2258.56
Price / Book0.015.168.665.87
Net Income-$3.10M$30.99M$3.25B$258.55M
7 Day Performance-3.34%7.74%4.20%2.23%
1 Month Performance-7.56%16.18%10.82%12.76%
1 Year Performance-82.49%-1.03%34.70%19.36%

China SXT Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SXTC
China SXT Pharmaceuticals
1.2378 of 5 stars
$1.59
-1.9%
N/A-82.2%$187.96M$1.93M0.0090Positive News
Gap Up
VIR
Vir Biotechnology
3.7018 of 5 stars
$5.50
-2.7%
$30.25
+450.0%
-43.0%$760.32M$74.21M-1.30580
KALV
KalVista Pharmaceuticals
4.1141 of 5 stars
$15.22
+4.8%
$26.29
+72.7%
+7.8%$760.24MN/A-4.12100High Trading Volume
AMLX
Amylyx Pharmaceuticals
3.2987 of 5 stars
$8.41
+9.5%
$11.75
+39.7%
+332.3%$749.68M-$1.27M-2.70200High Trading Volume
AVBP
ArriVent BioPharma
2.1702 of 5 stars
$21.87
+1.1%
$39.29
+79.6%
+4.6%$748.24MN/A-5.8040Positive News
Analyst Forecast
Analyst Revision
IMTX
Immatics
2.8128 of 5 stars
$6.11
+2.3%
$14.67
+140.0%
-47.9%$742.67M$168.65M-35.94260News Coverage
Positive News
IMNM
Immunome
1.9176 of 5 stars
$8.51
-1.5%
$23.33
+174.2%
-25.9%$740.46M$9.04M-2.6840Positive News
NUVB
Nuvation Bio
1.8672 of 5 stars
$2.15
-2.1%
$7.17
+232.7%
-30.1%$732.92M$7.87M-0.9260
MGTX
MeiraGTx
4.281 of 5 stars
$8.89
+5.0%
$24.00
+170.0%
+82.2%$714.40M$33.28M-3.83300Insider Trade
GYRE
Gyre Therapeutics
0.1574 of 5 stars
$7.61
+1.6%
N/A-51.0%$713.51M$105.76M380.6940Positive News
AUTL
Autolus Therapeutics
2.6058 of 5 stars
$2.65
+7.3%
$9.32
+251.7%
-38.5%$705.27M$10.12M-3.01330

Related Companies and Tools


This page (NASDAQ:SXTC) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners